The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
AACR 2023 | Phase Ib trial of ianalumab and ibrutinib in CLL
Kerry Rogers, MD, The Ohio State University, Columbus, OH, provides an overview of findings from a Phase Ib dose-escalation and -expansion trial (NCT03400176) of ianalumab, an anti-BAFF monoclonal antibody, and ibrutinib in patients with chronic lymphocytic leukemia (CLL). Ianalumab with ibrutinib was shown to have a good safety profile, and promising efficacy, where undetectable minimal residual disease (MRD) was reported in multiple patients. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
